Men's Health News

RSS

NYU Langone Medical Center announces establishment of Smilow Comprehensive Prostate Cancer Center

NYU Langone Medical Center is pleased to announce that it has established The Smilow Comprehensive Prostate Cancer Center with a $5 million gift from Joel E. Smilow, a member of the Board of Trustees at NYU Langone Medical Center and New York University. The Smilow Center is dedicated to providing comprehensive, state-of-the-art personalized care for men with prostate cancer as well as educating men and their families about the disease and the wide range of treatment options available today.

21 Oct 2010

Link between low testosterone and heart disease deaths: Study

In a new study it was seen that men diagnosed with coronary heart disease with low testosterone were almost twice as likely to die over a seven year period. The team led by Prof Kevin Channer a cardiologist of the Royal Hallamshire Hospital in Sheffield looked at 930 men for the study. This study is in contrast to the popular belief that testosterone increases heart disease risk. The study was published in the journal Online First Heart.

21 Oct 2010

Prostate cancer can risk of colon cancer: Study

Men with prostate cancer should be especially diligent about having routine screening colonoscopies, results of a new study by gastroenterologists at the University at Buffalo indicate.

20 Oct 2010

Researchers to study effectiveness of gamma-tocotrienol on prostate cancer cells

Survival rates of the world's most common cancer might soon be increased with a new vitamin E treatment which could significantly reduce tumour regrowth. Queensland University of Technology (QUT) prostate cancer researchers are leading the fight against a disease which kills 3000 Australian men a year.

20 Oct 2010

Tips to improve cellular prostate health

Prostate cancer is one of the most common cancers in America and may lead to more than 32,000 deaths this year. Medical Doctor and cancer expert, Dr. Isaac Eliaz announces breakthrough research and essential recommendations for the prevention and treatment of prostate cancer.

19 Oct 2010

Robot-assisted surgery effective for five-year prostate cancer control: Study

A first-ever, long-term study of patients who underwent robot-assisted surgery to remove their cancerous prostates found that nearly 87 percent of them had no recurrence of the disease after five years.

19 Oct 2010

Dopamine behind mens susceptibility to alcoholism

Alcohol is one of the most commonly abused substances, and men are up to twice as likely to develop alcoholism as women. Until now, the underlying biology contributing to this difference in vulnerability has remained unclear.

19 Oct 2010

Type 2 diabetes and insulin use associated with CRC risk in men, but not women

There is an association between type 2 diabetes mellitus and colorectal cancer (CRC) among men, but not women, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association (AGA) Institute.

19 Oct 2010

Robot-assisted brachytherapy for treating prostate cancer

In the first-of-a-kind clinical trial, a robot will be used to place therapeutic radioactive seeds in prostate cancer patients. The National Cancer Institute-supported study, which will enroll 14 patients, has just opened at Thomas Jefferson University Hospital.

15 Oct 2010

Scientists identify protein in urine can indicate prostate cancer risk

Cancer research UK scientists have shown that a protein in urine could be a powerful indicator of prostate cancer risk, according to a study published in PLoS ONE.

14 Oct 2010

New evidence supports possible link between XMRV and prostate cancer

Xenotropic murine leukemia virus-related virus (XMRV) has been the subject of many studies since its discovery in 2006, but conflicting reports have created an unclear picture of XMRV's role in human disease. In three recent studies published in the November 15 issue of The Journal of Infectious Diseases, now available online, the evidence supports a possible link between XMRV and prostate cancer but not other links involving chronic fatigue syndrome, HIV infection, or hepatitis C virus (HCV) infection.

13 Oct 2010

Australian women stressed and overweight: Survey

In a poll known as “Australia's Biggest Health Check” 26,000 responders showed that Australia's women feel stressed out and unfit and overworked. It also shows that they have barely half an hour of leisure time per day and the mismatch between how much sex women want versus what they get. The survey was promoted via two magazines - Women's Health and Prevention - and also had the backing of Priceline and the Seven Network’s Sunrise program. There were 24,500 women and 1,500 men in on the poll.

12 Oct 2010

Most men with prostate cancer not referred to hospice care early enough

More than half of men dying of prostate cancer use hospice care - a significant increase over the last two decades - but most wait too long to enroll so they can't take full advantage of the palliative care that could make their deaths easier, a study by researchers at UCLA's Jonsson Comprehensive Cancer Center found.

12 Oct 2010

Fertility concerns of cancer survivors inadequately addressed, study finds

Many cancer survivors experience changes in sexual function that leave them feeling guilty and a longing for intimacy, Australian researchers told at the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan, Italy. The researchers say that these sexuality and fertility concerns are often not adequately addressed by doctors.

11 Oct 2010

Abiraterone acetate improves survival in metastatic castration-resistant prostate cancer

Patients with metastatic castration-resistant prostate cancer who have progressed after chemotherapy live significantly longer if treated with the drug abiraterone acetate compared to placebo, the results of a large Phase-III clinical trial confirm.

11 Oct 2010

COU-AA-301 Phase 3 study demonstrates improvement in CRPC survival rate

Results from a pre-specified interim analysis of a randomized, placebo-controlled Phase 3 study, COU-AA-301, demonstrate that patients treated with the investigational agent abiraterone acetate plus low-dose prednisone/prednisolone showed a significant improvement in overall survival compared to patients treated with prednisone/prednisolone plus placebo.

11 Oct 2010

Rutgers University receives NIH grant to increase reliability of prostate cancer imaging

The National Institutes of Health has awarded a $3.3 million grant to a research team that includes Rutgers University to increase the reliability of imaging prostate cancer.

11 Oct 2010

Auxilium commences dosing in global XIAFLEX phase III program for Peyronie's disease

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced that the first subject has been dosed in the global phase III program of XIAFLEX® for the treatment of Peyronie's disease. Peyronie's disease is the development of scar tissue on the penis that can cause the penis to curve during erection, often interfering with or preventing intercourse and resulting in psychological distress or bother for the patient.

11 Oct 2010

CDC, national leaders issue recommendations to standardize testosterone tests

The use of testosterone assays for patient care and research is on the rise as new research links testosterone to a variety of diseases and conditions. Although the assays are heavily used, discrepancies and inaccuracies in measurements resulting from the various assays are widespread.

11 Oct 2010

Abiraterone Phase III clinical data to be presented at ESMO meeting

Attendees at next week's European Society of Medical Oncology (ESMO) meeting in Milan will be presented with top-line Phase III Clinical Trials data on Abiraterone in the treatment of castration-resistant prostate cancer.

8 Oct 2010